![logo](/logos/TERN.webp)
Terns Pharmaceuticals, Inc.
NASDAQ:TERN
7.81 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Terns Pharmaceuticals, Inc. |
Symbool | TERN |
Munteenheid | USD |
Prijs | 7.81 |
Beurswaarde | 549,604,539 |
Dividendpercentage | 0% |
52-weken bereik | 3.26 - 10.03 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Erin Quirk M.D. |
Website | https://www.ternspharma.com |
An error occurred while fetching data.
Over Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)